All In MedTech

FDA Clearance Tracker · P050038-S004

ARISTA AH ABSORBABLE HEMOSTAT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 14, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 14, 2008

Approved

Time to decision

59 days

Received Nov 16, 2007. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P050038-S004
Device name
ARISTA AH ABSORBABLE HEMOSTAT
Applicant
Davol, Inc.
Applicant location
Warwick, RI
Received
Nov 16, 2007
Decided
Jan 14, 2008
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P050038

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED AT ENPATH MEDICAL, INC., MINNEAPOLIS, MINNESOTA TO PERFORM FILLING, PACKAGING, AND LABELING OF THE DEVICE.

Source documents

Other decisions for Davol, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.